Verona Pharma plc
VRNA
$58.92
$0.621.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 36.64M | 5.62M | -- | -- | -- |
| Total Other Revenue | 18.00K | -- | -- | -- | -- |
| Total Revenue | 36.66M | 5.62M | -- | -- | -- |
| Cost of Revenue | 2.04M | 543.00K | -- | -- | -- |
| Gross Profit | 34.62M | 5.08M | -- | -- | -- |
| SG&A Expenses | 45.09M | 35.20M | 49.04M | 20.43M | 14.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.44M | 44.68M | 67.58M | 26.61M | 18.06M |
| Operating Income | -17.78M | -39.06M | -67.58M | -26.61M | -18.06M |
| Income Before Tax | -25.56M | -42.71M | -69.82M | -25.04M | -14.19M |
| Income Tax Expenses | 8.27M | 250.00K | 1.01M | 754.00K | -53.00K |
| Earnings from Continuing Operations | -33.83M | -42.96M | -70.84M | -25.79M | -14.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.83M | -42.96M | -70.84M | -25.79M | -14.13M |
| EBIT | -17.78M | -39.06M | -67.58M | -26.61M | -18.06M |
| EBITDA | -17.52M | -38.79M | -67.31M | -26.35M | -17.85M |
| EPS Basic | -3.26 | -4.22 | -6.99 | -2.56 | -1.41 |
| Normalized Basic EPS | -0.19 | -0.33 | -0.51 | -0.19 | -0.11 |
| EPS Diluted | -3.52 | -4.22 | -6.99 | -2.56 | -1.68 |
| Normalized Diluted EPS | -0.19 | -0.33 | -0.51 | -0.19 | -0.11 |
| Average Basic Shares Outstanding | 82.91M | 81.49M | 81.03M | 80.71M | 80.27M |
| Average Diluted Shares Outstanding | 10.36M | 10.19M | 10.13M | 10.09M | 10.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |